Orthostatic Hypotension and POTS Both Cause Dizziness on Standing. They Are Different Conditions with Different Treatments.

The Scene

The patient in this scene is a composite. Names, ages, and circumstances are changed to protect privacy.

Priya is 29 years old and she is standing in the shower when the room goes gray. She grabs the wall. The graying resolves in about ten seconds. She sits down on the shower floor and stays there for a minute before she feels safe standing again.

This has been happening for eight months. Not every time she stands up. But enough. She has started showering with the water cooler, sitting up slowly in bed in the morning before getting vertical, drinking more water than she used to. She has modified her life around this symptom the way people adapt to a thing they have learned to live with.

She describes something else to me at the appointment. When she stands up, her heart races. She can feel it. Her FitBit shows her heart rate jumping from 65 lying down to 105 within two minutes of standing. She does not feel lightheaded when this happens, just aware of the pounding.

She had COVID-19 sixteen months ago. A mild case. Fully recovered within two weeks, she thought.

The symptoms began four months after the infection.

Priya has two distinct but related phenomena. The racing heart with standing is postural tachycardia: her heart rate increases more than 30 beats per minute within 10 minutes of standing without a significant drop in blood pressure. That is the definition of POTS. The gray episodes in the shower are a different mechanism: vasodilatory orthostatic stress in a warm environment that exceeds her compensatory reserve. She does not have orthostatic hypotension by strict criteria, but she has a failure of orthostatic hemodynamic defense.

Her condition has a name. It has a mechanism. It has treatments that work. The eighteen months of adapting to the symptom were not necessary.

What It Is

Orthostatic Hypotension

Orthostatic hypotension (OH) is a sustained drop in blood pressure of at least 20 mmHg systolic or 10 mmHg diastolic within three minutes of standing or passive tilt to at least 60 degrees 5 / Solid . The operative word is “sustained”: a brief transient dip at the moment of standing can occur in healthy people and does not meet diagnostic criteria.

Orthostatic hypotension is not a rare condition in the elderly. In community-based studies, prevalence ranges from 5% in adults under 65 to 20-30% in adults over 70 5 / Solid . It is not a benign finding in this population. Orthostatic hypotension is independently associated with falls, syncope, cognitive impairment, and cardiovascular mortality 5 / Solid .

Postural Tachycardia Syndrome (POTS)

POTS is a chronic orthostatic intolerance syndrome characterized by an increase in heart rate of at least 30 beats per minute (or to a rate above 120 bpm) within 10 minutes of standing, in the absence of orthostatic hypotension, and in the presence of orthostatic symptoms 5 / Solid . The symptoms include palpitations, lightheadedness, blurred vision, mental fogginess (“brain fog”), nausea, tremulousness, and fatigue with standing.

The key distinction between POTS and orthostatic hypotension: in POTS, blood pressure is maintained. The heart compensates for inadequate venous return by accelerating. The price of that compensation is the symptomatic pounding and the cardiovascular effort that produces fatigue.

POTS predominantly affects women (female-to-male ratio approximately 5:1) and is most prevalent in the 15-50 age range 5 / Solid . It is estimated to affect 1-3 million Americans, though systematic epidemiological data are limited.

Post-COVID POTS

The COVID-19 pandemic produced a significant surge in POTS diagnoses. Multiple cohort studies identified new-onset POTS in patients following SARS-CoV-2 infection, with post-COVID autonomic dysfunction becoming a recognized component of long COVID 4 / Promising .

The mechanisms proposed for post-COVID POTS include: autoimmune disruption of adrenergic receptors, direct ganglionic injury by the virus, mast cell activation, and hypovolemia from prolonged bed rest during acute illness. These mechanisms are not mutually exclusive and may coexist in different patients 3 / Early .

Post-COVID POTS appears to follow a somewhat different course from classic POTS: a proportion of patients improve significantly over 6-12 months, whereas idiopathic POTS often persists for years 3 / Early .

The Mechanism

The Normal Response to Standing

Standing up shifts approximately 500-700 mL of blood from the thorax into the capacitance vessels of the lower extremities and splanchnic bed. This venous pooling reduces venous return to the heart, which reduces stroke volume and tends to drop cardiac output and blood pressure transiently.

The normal response occurs within seconds. Baroreceptors in the carotid sinus and aortic arch detect the blood pressure drop and signal the autonomic nervous system. The result: increased heart rate (5-10 bpm is normal), increased cardiac contractility, peripheral arterial vasoconstriction, and venoconstriction to mobilize venous blood back toward the heart. This is the baroreflex-mediated orthostatic response. It works so quickly and effectively in healthy people that they never notice it.

Why the Response Fails in Orthostatic Hypotension

In orthostatic hypotension, the baroreflex-mediated response is insufficient. Several failure mechanisms:

Neurogenic orthostatic hypotension: Autonomic neuropathy impairs the efferent sympathetic response to baroreceptor activation. The blood pressure drops because the vasoconstriction and cardioacceleration signals never arrive. Causes include Parkinson’s disease, multiple system atrophy, pure autonomic failure, diabetes mellitus (autonomic neuropathy), and amyloidosis. Neurogenic OH is identified by its failure of the normal heart rate increase: when blood pressure drops without the expected compensatory tachycardia, the autonomic system is not responding 5 / Solid .

Medication-induced: The most common cause of OH in clinical practice. Antihypertensives (particularly alpha-blockers, nitrates, phosphodiesterase inhibitors), diuretics (volume depletion), tricyclic antidepressants, and dopaminergic agents (levodopa) all impair orthostatic hemodynamic defense.

Volume depletion: Inadequate intravascular volume from dehydration, blood loss, adrenal insufficiency, or diabetes insipidus.

Age-related changes: Baroreceptor sensitivity decreases with age, arterial compliance decreases, and venous compliance may increase, all of which impair the orthostatic response. Heat, physical deconditioning, prolonged bed rest, and large meals exacerbate age-related OH.

Why POTS Is Different

In POTS, the baroreflex and sympathetic efferents are not globally impaired. Instead, several specific mechanisms drive pathological tachycardia:

Hypovolemic POTS (most common, approximately 50% of cases): Reduced plasma volume, reduced red blood cell mass. When less blood is available to fill the venous capacitance vessels, more compensatory tachycardia is required to maintain cardiac output 5 / Solid . Patients with hypovolemic POTS often have lower plasma volume than age- and sex-matched controls even at rest.

Hyperadrenergic POTS (approximately 10% of cases): Excess norepinephrine levels with standing (plasma norepinephrine above 600 pg/mL upright). These patients have prominent symptoms of sympathetic activation including tremor, anxiety, and marked hypertension with standing in addition to tachycardia.

Neuropathic POTS (approximately 40% of cases): Partial sympathetic denervation of the lower-extremity and splanchnic vessels, producing excessive venous pooling with standing. The heart compensates with tachycardia. These patients have normal plasma volume but abnormal blood distribution.

Autoimmune POTS: Autoantibodies against adrenergic receptors (alpha-1 and beta-2 adrenergic receptor antibodies) have been found in higher frequencies in POTS patients than controls 3 / Early . This mechanism may be particularly relevant in post-COVID POTS.

How We Diagnose It

The Bedside Orthostatic Vital Signs

The most basic diagnostic test is free: measure blood pressure and heart rate after 5 minutes of supine rest, then at 1 and 3 minutes of standing.

For orthostatic hypotension: a drop of 20 mmHg systolic or 10 mmHg diastolic at 1 or 3 minutes, confirmed on at least two separate occasions.

For POTS: a heart rate increase of 30 bpm or more (or 40 bpm or more in adolescents aged 12-19) within 10 minutes of standing, without a significant blood pressure drop, on at least two separate occasions.

The caveat: orthostatic vital signs in the office are commonly taken incorrectly. Blood pressure measurements must be taken with a properly calibrated automated device or manually by a skilled examiner. The patient must have been supine for at least 5 minutes. One reading is insufficient; serial readings through 3 minutes are needed to capture delayed orthostasis.

The Tilt-Table Test

When bedside orthostatic vital signs are equivocal or when precise characterization is needed (particularly for POTS phenotyping), the tilt-table test provides a standardized assessment. The patient lies on a motorized table that tilts to 70 degrees passive head-up tilt for 45 minutes, with blood pressure and heart rate monitoring throughout. Optional pharmacological provocation (sublingual nitroglycerin or isoproterenol) can be added.

The tilt-table test is the reference standard for diagnosing vasovagal syncope, orthostatic hypotension, and POTS. It is performed in electrophysiology laboratories and autonomic function units. Access in central Illinois: Carle Foundation Hospital, OSF Saint Francis in Peoria, and Saint Louis University Hospital for more complex cases.

Additional Testing

When neurogenic OH is suspected, formal autonomic function testing includes quantitative sudomotor axon reflex testing (QSART, measures postganglionic sudomotor function), heart rate responses to deep breathing and Valsalva maneuver (quantify cardiac vagal function), and the Valsalva ratio. This full autonomic battery is available at specialized autonomic centers (Mayo Clinic Rochester, Vanderbilt Autonomic Dysfunction Center).

For POTS phenotyping, 24-hour urine sodium provides an indirect measure of salt balance and helps identify hypovolemic subtypes. Plasma norepinephrine levels supine and upright (hyperadrenergic subtype > 600 pg/mL upright). Plasma volume measurement (Cr-51-labeled albumin dilution) is available at research centers.

The Evidence

Treatment of Orthostatic Hypotension

Nonpharmacological: Physical counterpressure maneuvers (crossing legs, tensing leg muscles, sitting on the edge of the bed before standing) reduce blood pressure drop by raising venous return 5 / Solid . Compression stockings and abdominal binders reduce venous pooling 5 / Solid . Adequate salt and fluid intake expands plasma volume. Small, frequent meals (large meals divert blood to the splanchnic bed, a known OH trigger).

Pharmacological:

• Fludrocortisone: Synthetic mineralocorticoid that promotes sodium and fluid retention. Effective for neurogenic OH and hypovolemic states. Side effects: supine hypertension, hypokalemia, fluid overload. Starting dose 0.05-0.1 mg daily 5 / Solid .
• Midodrine: Peripheral alpha-1 agonist that constricts both arterioles and veins, reducing venous pooling and raising blood pressure. FDA-approved for OH. Does not cross the blood-brain barrier. Side effects: supine hypertension (do not take within 4 hours of bedtime), scalp tingling (piloerection). Starting dose 2.5-5 mg two to three times daily 5 / Solid .
• Droxidopa (Northera): A norepinephrine prodrug, FDA-approved for neurogenic OH in Parkinson’s disease, multiple system atrophy, and pure autonomic failure. Particularly useful when both blood pressure support and avoidance of supine hypertension are priorities.

Treatment of POTS: The Evidence Base

The POTS treatment evidence is thinner than for essential hypertension, reflecting the relative rarity of the condition and the heterogeneous mechanisms. No single treatment is uniformly effective.

Salt and fluid loading: The simplest and most universally recommended first step. Patients with hypovolemic POTS are instructed to consume 2-3 liters of fluid and 3-5 grams of additional dietary sodium daily 5 / Solid . The evidence base is primarily observational and physiologically grounded.

Exercise training: One of the most durable POTS treatments. A formal exercise program beginning with recumbent exercise (rowing, swimming, recumbent cycling) to avoid orthostatic stress, gradually progressing to upright exercise, has been shown to significantly reduce heart rate response to standing and improve quality of life 5 / Solid . The Levine protocol (12-week exercise program designed for POTS) remains a reference standard.

Beta-blockers: Low-dose propranolol (10-20 mg) before anticipated orthostatic stress has evidence from the randomized trials 4 / Promising . The mechanism is rate reduction (which improves stroke volume at a given heart rate), not volume expansion. Higher doses of beta-blockers can worsen POTS by reducing cardiac output.

Ivabradine: A selective funny current (If) inhibitor that reduces heart rate without affecting blood pressure or myocardial contractility. It has shown benefit in POTS in small randomized trials 3 / Early and is increasingly used in clinical practice for the hyperadrenergic and neuropathic subtypes where beta-blockade is not tolerated. Starting dose 2.5-5 mg twice daily.

Fludrocortisone and midodrine are also used in POTS, primarily for the hypovolemic subtype.

For post-COVID POTS: A conservative, graduated approach is recommended. Aggressive pharmacotherapy before allowing natural recovery over 6-12 months is not supported. Salt and fluid loading, compression garments, and graduated exercise are first-line. Persistent symptoms at 12 months warrant more aggressive evaluation 3 / Early .

The Patient Experience

The Symptom Burden of POTS

POTS is significantly disabling. Patients report exercise intolerance, cognitive dysfunction, palpitations, chronic fatigue, and social withdrawal. Quality of life scores in POTS cohorts are comparable to those of patients with congestive heart failure 5 / Solid .

The psychological burden is compounded by the diagnostic odyssey most POTS patients experience. The average time from symptom onset to diagnosis of POTS is 4-5 years 4 / Promising . Patients are frequently told their symptoms are anxiety, panic disorder, or deconditioning without a proper orthostatic assessment.

Priya’s case is not unusual. She adapted to her symptoms for eighteen months before receiving a diagnosis. In that time, she modified her behavior to avoid orthostatic stress, which paradoxically reduced her exercise tolerance and worsened her deconditioning, which worsened her POTS.

What the Patient Notices Day to Day

Patients with POTS often describe specific situational triggers: hot showers (heat causes peripheral vasodilation), prolonged standing (grocery checkout lines are commonly cited), large meals, alcohol. They develop intuitive countermeasures: keeping water nearby, sitting whenever possible, wearing compression garments, eating smaller meals.

These compensatory adaptations are valid short-term strategies. They are not a substitute for diagnosis and treatment. A patient who has learned to avoid showers does not need to avoid showers forever; they need a physiological explanation for why heat worsens their symptoms and a treatment plan that addresses the underlying mechanism.

Decisions and Trade-Offs

POTS vs Anxiety: The Diagnostic Trap

POTS symptoms (palpitations, tremulousness, lightheadedness, fatigue) overlap substantially with anxiety disorder symptoms. This overlap has contributed to the diagnostic delay. The critical distinction: anxiety produces tachycardia that is not specifically triggered by postural change. POTS tachycardia is orthostatic by definition. A physician who measures heart rate supine and standing in a patient with “anxiety” and palpitations will either confirm POTS (heart rate rises 30+ bpm on standing) or help exclude it.

The two conditions can coexist. Anxiety is more prevalent in POTS patients than in the general population, partly because of the psychological burden of a chronic dysautonomic condition, and partly because of shared sympathetic activation. Treating anxiety without addressing the POTS physiology leaves patients symptomatic.

When Ivabradine Versus Beta-Blockers

Beta-blockers and ivabradine both reduce heart rate but through different mechanisms. Beta-blockers also reduce blood pressure and cardiac contractility, which can worsen fatigue and exercise tolerance in POTS. Ivabradine reduces rate specifically through the SA node without the peripheral effects.

The practical guidance:

• For hyperadrenergic POTS with prominent blood pressure elevation and sympathetic symptoms: low-dose propranolol is rational (it addresses both rate and adrenergic excess)
• For POTS with normal or low blood pressure and prominent fatigue: ivabradine is preferred
• For POTS in patients with concurrent reactive airway disease: ivabradine (beta-blockers relatively contraindicated)

Pregnancy and POTS

POTS frequently worsens in early pregnancy (due to progesterone-mediated vasodilation and early volume shifts) and often improves in the second and third trimester as plasma volume expands. Midodrine and fludrocortisone require careful consideration in pregnancy; neither is well-studied in this context. Ivabradine has not been adequately studied in human pregnancy. Nonpharmacological management and specialist input are appropriate for pregnant patients with POTS.

Clinical Synthesis

Orthostatic hypotension and POTS represent an area of cardiovascular medicine where the gap between symptom recognition and diagnosis remains wide. Neither condition is diagnosed by the blood pressure check that most patients receive at a routine office visit. Both require a specific assessment that is rarely performed unless the physician thinks to ask.

This clinical approach to autonomic dysregulation begins with a basic question that costs nothing and takes 10 minutes: measure heart rate and blood pressure supine and at 1, 3, and 5 minutes of standing. In a patient with unexplained lightheadedness, near-syncope, palpitations with standing, or chronic fatigue with positional component, this single maneuver provides the physiological diagnosis or excludes it.

For the 1-3 million Americans with POTS, many of whom have spent years being told their symptoms are anxiety or deconditioning, a proper orthostatic evaluation is not a luxury. It is the minimum standard of care.

Post-COVID autonomic dysfunction has expanded the population at risk. Patients who had COVID-19 and subsequently developed orthostatic symptoms should be evaluated for POTS and neurogenic OH, not reassured that their symptoms will resolve. Some will resolve. Some will not. The evaluation tells you which you are dealing with.

For the older patient with orthostatic hypotension, the clinical emphasis is on medication review (antihypertensives, diuretics, alpha-blockers, tricyclics) and on fall prevention. Orthostatic hypotension in a 72-year-old on three antihypertensive medications is often iatrogenic. Reducing or stopping the blood pressure medication that is producing OH may be more beneficial than treating the falls that result from it.

Extended Evidence Review: POTS and Orthostatic Intolerance Therapies

The Levine Exercise Protocol: The Strongest Evidence in POTS Management

The Levine Protocol (formally the Dallas POTS exercise training protocol) is a structured 3-month progressive exercise program developed by Benjamin Levine at UT Southwestern, based on his observation that many POTS patients have a “reconditioning” phenotype: a small, deconditioned heart that handles orthostatic stress poorly due to reduced stroke volume reserve.

The program combines rowing or swimming (horizontal exercise that allows training without standing-induced symptoms) with recumbent cycling, progressing to standing exercises and ultimately to upright aerobic exercise as cardiac conditioning improves over weeks. The protocol was evaluated in a randomized controlled trial of 68 POTS patients: exercise training produced significant improvements in upright peak VO2, stroke volume during tilt table testing, heart rate response to upright standing, and patient-reported quality of life compared to controls. 5 / Solid

The magnitude of improvement is substantial: approximately 70% of participants who completed the protocol reported significant improvement in daily function. A proportion achieved sufficient improvement that they no longer met diagnostic criteria for POTS at 3 months. This is the most clinically meaningful result in POTS management, and it requires no pharmacological intervention.

The practical challenge: the protocol requires motivated patients, access to rowing or swimming facilities, and willingness to accept an initial period of worsened symptoms as conditioning begins. Many symptomatic POTS patients struggle to initiate exercise because upright activity precipitates their symptoms. The horizontal nature of the early protocol phases addresses this: rowing and swimming in semi-supine or horizontal positions allow cardiovascular training without the orthostatic stress.

Ivabradine in POTS

Ivabradine (Corlanor) is an I_f channel (funny current) blocker in the sinoatrial node that selectively reduces heart rate without affecting blood pressure, contractility, or AV conduction. Unlike beta-blockers (which reduce heart rate by blocking adrenergic stimulation), ivabradine reduces the intrinsic pacemaker rate directly.

In POTS, the abnormal compensatory tachycardia upon standing is driven by a combination of excess adrenergic stimulation and reduced vagal tone. Ivabradine reduces the heart rate component without worsening the hypotension that sometimes complicates beta-blocker use in POTS patients with vasodepressor features.

Evidence: Several small, randomized trials and case series have demonstrated that ivabradine reduces orthostatic tachycardia and symptom burden in POTS. A crossover trial by Taub et al. (2012) in 21 POTS patients showed significant reduction in standing heart rate and improvement in symptom scores with ivabradine compared to placebo. 4 / Promising A larger open-label registry analysis of 53 POTS patients confirmed improvement in functional status and symptom scores over 4-6 weeks of ivabradine.

Ivabradine is used off-label for POTS (its FDA-approved indication is heart failure with reduced ejection fraction). It is particularly useful for patients with hyperadrenergic POTS (the subtype characterized by standing norepinephrine above 600 pg/mL), in whom beta-blockers sometimes produce intolerable hypotension or worsening of fatigue.

Midodrine and Fludrocortisone: The Volume-Expansion Strategy

POTS frequently coexists with or is driven by reduced plasma volume. The management strategy of volume expansion aims to increase preload and reduce orthostatic tachycardia through improved venous return.

Fluid and sodium loading: The first-line intervention in most guidelines. Patients are advised to drink 2-3 liters of fluid daily and consume 3-5 grams of sodium daily. This strategy can be implemented immediately without prescription and produces meaningful improvement in symptoms within days in sodium-deficient POTS patients.

Fludrocortisone: A mineralocorticoid receptor agonist that promotes renal sodium and water retention. Starting dose 0.1 mg daily; may be increased to 0.2 mg. Fludrocortisone increases plasma volume over days to weeks. Adverse effects include hypokalemia, dependent edema, headache, and supine hypertension. It is contraindicated in severe hypertension, heart failure, and conditions where sodium retention is harmful. 4 / Promising

Midodrine: An alpha-1 adrenergic agonist that produces peripheral vasoconstriction, reducing venous pooling in the lower extremities and increasing venous return to the heart. It reduces orthostatic tachycardia by improving preload. Dose: 2.5-10 mg three times daily (taken during waking hours; must not be taken within 4 hours of recumbency due to supine hypertension risk). Adverse effects: piloerection, urinary retention, and tingling scalp (all from alpha-1 activation). 4 / Promising

Beta-Blockers: Low-Dose Propranolol

Low-dose propranolol (10-20 mg twice daily) reduces the compensatory tachycardia of POTS without the hypotensive effects of higher doses. A small randomized trial by Raj et al. showed that low-dose propranolol significantly reduced standing heart rate in POTS, though patients with hyperadrenergic POTS (high standing norepinephrine) had less symptom improvement compared to those with neuropathic POTS. 4 / Promising

The nuance: beta-blockade reduces tachycardia but does not improve the fundamental orthostatic hypotension or impaired venous return. In POTS subtypes where the tachycardia is the primary symptom driver, propranolol is effective. In subtypes where the underlying problem is impaired venous return or reduced plasma volume, the tachycardia is compensatory and reducing it without addressing the underlying cause may worsen symptoms.

Extended Mechanism: POTS Subtypes and Their Distinct Pathophysiology

The Four Major POTS Subtypes

POTS is not a single disease but a clinical syndrome with multiple distinct pathophysiological mechanisms:

Neuropathic POTS (most common, approximately 50%): Partial dysautonomia with loss of adrenergic innervation in the lower limb vasculature, producing impaired peripheral vasoconstriction during standing. The heart compensates with tachycardia to maintain cardiac output. Plasma norepinephrine levels during standing are typically normal. Associated with small fiber peripheral neuropathy in some patients (confirmed by skin biopsy). 5 / Solid

Hyperadrenergic POTS (approximately 30%): Excess sympathetic nervous system activation during standing, producing standing plasma norepinephrine above 600 pg/mL (vs normal below 300). These patients often experience tremor, palpitations, anxiety, and hypertension with standing rather than hypotension. The cause may include mutations in the norepinephrine transporter (NET) gene or other mechanisms of impaired norepinephrine reuptake.

Hypovolemic POTS: Low plasma volume as the primary driver. These patients often respond well to volume expansion therapy. May be associated with states of chronic volume depletion (inadequate fluid intake, excessive sweating, or renal sodium wasting).

POTS in connective tissue disorders: Particularly hypermobile Ehlers-Danlos syndrome (hEDS). The loose connective tissue in hEDS produces excess venous distensibility, pooling blood in the lower extremities during standing. POTS is substantially more prevalent in hEDS patients than in the general population. Management includes compression garments, abdominal binders, and careful exercise training.

Post-COVID POTS

Following COVID-19 infection, a significant proportion of patients who develop long COVID syndrome (Long COVID) report new onset of orthostatic intolerance, fatigue, and tachycardia consistent with POTS. Population-level data show that the incidence of POTS diagnosis has increased substantially since 2020-2021, with post-COVID cases representing a meaningful portion of new cases.

The proposed mechanisms include: autonomic nervous system dysfunction from direct viral or inflammatory injury to autonomic ganglia, autoantibodies against adrenergic receptors (anti-beta-2 adrenoreceptor and anti-muscarinic antibodies have been detected in some post-COVID POTS patients), microclot-associated microvascular dysfunction, and mast cell activation.

The management of post-COVID POTS follows the same principles as idiopathic POTS: exercise training, salt and fluid loading, volume expansion agents, and heart rate-reducing agents. A proportion of post-COVID POTS patients experience gradual improvement over 12-24 months. 3 / Early

Extended Patient Experience: Post-COVID POTS at Carle

In the post-pandemic period, Carle Foundation Hospital’s dysautonomia and neurology clinics have seen substantially increased referrals for new-onset POTS in patients who experienced COVID-19 infections. A significant portion of these patients are young women (consistent with the pre-pandemic POTS demographic) who developed symptoms 4-12 weeks after acute COVID infection.

The evaluation at Carle includes: tilt table testing for diagnostic confirmation, 24-hour Holter monitoring to characterize the arrhythmia pattern, and a referral to occupational therapy and physical therapy for graduated reconditioning using the Levine protocol framework. When symptoms are severe, cardiology and neurology collaborate on pharmacological management. Northwestern Medicine’s autonomic disorders program in Chicago is used for referral of complex or refractory cases.

Patient education at Carle emphasizes:

1. The condition is real, measurable, and responds to systematic management
2. Exercise training is the cornerstone, not the afterthought
3. Gradual improvement is expected in most cases, though the timeline varies
4. Salt, hydration, and positioning strategies (increasing the head of the bed 30 degrees to reduce nighttime volume shifts, sitting on the edge of the bed before standing) are daily self-management tools

Extended Mechanism: Orthostatic Hypotension Pathophysiology in Older Adults

Neurogenic vs Non-Neurogenic Orthostatic Hypotension

Orthostatic hypotension (OH) in the elderly is common, often underdiagnosed, and carries significant consequences. The definition: sustained fall in systolic BP of at least 20 mmHg or diastolic BP of at least 10 mmHg within 3 minutes of standing, confirmed on at least two occasions.

Neurogenic OH arises from impaired sympathetic activation during orthostasis: the normal reflex arc (baroreceptor sensing, brainstem processing, sympathetic efferent output, norepinephrine release, vasoconstriction and heart rate increase) is disrupted at the level of the autonomic nervous system. Causes include Parkinson’s disease (alpha-synuclein deposition in sympathetic ganglia), multiple system atrophy (olivopontocerebellar and striatonigral degeneration with autonomic failure), pure autonomic failure, diabetic autonomic neuropathy, and amyloid neuropathy. In neurogenic OH, heart rate does not rise appropriately during the BP fall (an absent or blunted compensatory tachycardia). 5 / Solid

Non-neurogenic OH occurs with an intact autonomic reflex arc but insufficient venous return or cardiac output to compensate for gravity-induced blood pooling. Common causes: volume depletion (dehydration, diuretic overuse), heart failure, prolonged bed rest, and venous insufficiency. Heart rate rises appropriately (baroreceptor reflex is intact) but the BP cannot be maintained because the stroke volume is insufficient.

Drug-induced OH: Multiple antihypertensives produce or exacerbate orthostatic hypotension: alpha-1 blockers (doxazosin, terazosin) are the most common culprits; high-dose ACE inhibitors, ARBs, and diuretics in volume-depleted patients; beta-blockers that blunt the compensatory heart rate rise; and anti-parkinsonian dopaminergic drugs (levodopa, dopamine agonists) that have peripheral vasodilatory effects. A medication review is mandatory in any patient with OH.

The Falls Connection

Orthostatic hypotension in older adults is a significant contributor to falls and fall-related injury (hip fracture, subdural hematoma). A 10-year prospective study of community-dwelling older adults found that orthostatic hypotension doubled the odds ratio for falls, independent of other fall risk factors. 5 / Solid

The clinical implication: every fall evaluation in an older adult should include orthostatic blood pressure assessment. Standing BP should be measured at 1 minute and 3 minutes after rising, as delayed OH (occurring after 3 minutes of standing) is more common in older adults and often missed by the standard 1-minute measurement.

Treatment of OH to reduce fall risk: gradually reduce or eliminate offending drugs; ensure adequate hydration; recommend compression stockings (waist-high, 30-40 mmHg pressure) and abdominal binders; head-of-bed elevation 15-30 degrees at night (reduces overnight sodium diuresis and improves morning supine-to-standing volume); physical counter-maneuvers (leg crossing, squatting, foot dorsiflexion); and pharmacological options for symptomatic neurogenic OH (droxidopa [Northera], midodrine, pyridostigmine).

Extended Evidence Review: Exercise Training as the Cornerstone of POTS Management

The Levine Protocol in Detail

The Levine reconditioning protocol: developed by Benjamin Levine at UT Southwestern and referred to formally as the Dallas POTS training program: is now supported by the strongest evidence base of any non-pharmacological POTS intervention. The 2018 RCT (Shaffer et al., JACC) enrolled 68 POTS patients randomized to exercise training versus propranolol for 3 months.

The protocol’s structure is designed to work around POTS patients’ primary limitation: upright exercise triggers symptoms (palpitations, lightheadedness, presyncope) that limit intensity and duration. The protocol begins exclusively in the supine and semi-supine positions:

Months 1-2: Supine and semi-recumbent phase

• Rowing (most common modality: recumbent with minimal upright component)
• Swimming (horizontal body position throughout)
• Recumbent cycling (reduces the hydrostatic stress of upright positioning)
• Start at 30 minutes, 3 times per week
• Progress by 5-minute increments per week as tolerated

Month 2-3: Introduce upright exercise

• Treadmill walking at low grade
• Upright cycling at low resistance
• Progressive increase in upright time as orthostatic tolerance improves

Concurrent strength training: Lower limb and core strengthening is added from month 2. Skeletal muscle in the lower limbs serves as an auxiliary venous pump (the “muscle pump”) that compresses deep venous capacitance vessels and returns blood to the central circulation. Strengthening lower limb muscles increases the effectiveness of this pump, reducing the venous pooling that underlies orthostatic intolerance.

The 2018 RCT results: exercise training produced greater improvement in peak oxygen consumption (VO2max, a direct measure of cardiovascular deconditioning correction), greater reduction in heart rate orthostatic increment, and better quality-of-life scores than propranolol after 3 months. Both interventions improved symptoms compared to baseline, but exercise training produced superior physiological improvement. 5 / Solid Long-term follow-up showed sustained improvement at 1 year in exercise-trained patients, whereas propranolol effects waned after drug discontinuation.

Post-COVID POTS: Distinct Features and Management Implications

Post-COVID POTS (or COVID-associated dysautonomia) emerged as a recognized clinical entity in 2020-2021 as clinicians observed that a subset of patients recovering from COVID-19 developed new-onset POTS weeks to months after acute infection. The pathophysiology is not fully established, but leading hypotheses include:

1. Autoimmune dysautonomia: SARS-CoV-2 infection may trigger autoantibodies against adrenergic receptors (alpha-1 adrenergic receptor, beta-2 adrenergic receptor, and muscarinic receptors), impairing sympathetic regulation of vascular tone. Serum autoantibodies against these receptors have been found at higher prevalence in post-COVID POTS patients than controls in several small studies. 3 / Early

2. Small fiber neuropathy: Skin punch biopsies from some long-COVID patients with dysautonomia have shown reduced intraepidermal nerve fiber density, suggesting a peripheral neuropathic mechanism consistent with neuropathic POTS.

3. Mast cell activation: Raised histamine, tryptase, and prostaglandins have been found in some post-COVID POTS patients, suggesting a role for mast cell activation syndrome (MCAS) in sustaining symptoms.

The clinical management of post-COVID POTS follows the same framework as idiopathic POTS: exercise reconditioning (Levine protocol), salt and fluid loading, compression garments, and pharmacological support where needed. Antihistamines may provide additional benefit in patients with features of mast cell activation (skin flushing, urticaria, gastrointestinal symptoms co-occurring with orthostatic symptoms).

The most important message for patients and clinicians: post-COVID POTS frequently improves significantly over 6-12 months with systematic management. It is not a permanent condition in most cases. Early structured reconditioning started within weeks of diagnosis improves outcomes more than delayed intervention.

Extended Mechanism: Orthostatic Physiology in the Context of Aging

How Normal Aging Impairs Orthostatic Tolerance

Normal aging impairs orthostatic cardiovascular compensation through several mechanisms:

1. Reduced baroreceptor sensitivity: The arterial baroreceptors (carotid sinus, aortic arch) become less sensitive with age, producing a slower and smaller heart rate response to acute blood pressure changes. The normal compensatory tachycardia on standing is blunted.

2. Reduced venous capacitance and vasoconstrictor response: Aging reduces the vasoconstriction response to adrenergic stimulation. Venoconstriction: the ability of veins to reduce their compliance and return pooled blood to the central circulation on standing: is impaired.

3. Reduced renal sodium conservation: Older adults have reduced aldosterone responsiveness, lower renin levels, and reduced tubular sodium reabsorption, producing less sodium retention during upright posture and contributing to lower circulating volume.

4. Structural cardiac changes: Age-related left ventricular stiffening impairs early diastolic filling (which fills the left ventricle passively as blood returns from the venous capacitance vessels). When venous return is reduced by orthostatic pooling, the stiff heart cannot compensate through increased filling: cardiac output falls more than in a younger heart.

The combination of these four mechanisms explains why orthostatic hypotension prevalence rises dramatically with age: approximately 5% at age 50-60, 20-30% at age 70-80, and above 30% at age 85 and older.

Pharmacological Management of POTS: Beyond the Basics

For patients who do not improve sufficiently with exercise, salt loading, fluid loading, and compression garments, pharmacological options include:

Ivabradine (Corlanor): An If (funny current) channel inhibitor that selectively slows heart rate. Unlike beta-blockers, it does not impair vasodilation or worsen orthostatic tolerance. In POTS, ivabradine reduces the excessive tachycardia on standing without blocking the compensatory vasoconstrictive reflex: which makes it preferable to beta-blockers in neuropathic POTS. A pilot RCT (n=22) showed heart rate reduction and symptom improvement over 8 weeks. 4 / Promising Ivabradine is off-label for POTS but widely used in specialist autonomic clinics.

Fludrocortisone: A synthetic mineralocorticoid that promotes renal sodium retention, expanding plasma volume. Dose: 0.1-0.2 mg daily. The most common initial pharmacological choice in hypovolemic POTS. Key limitation: supine hypertension (which is common in POTS and worsened by volume expansion). Monitor for hypokalemia.

Midodrine: An alpha-1 adrenergic agonist that produces peripheral vasoconstriction, reducing venous pooling on standing. Dose: 2.5-10 mg three times daily (must be taken during waking hours only: midodrine causes supine hypertension and should not be taken within 4 hours of lying down). Particularly useful for neuropathic POTS.

Propranolol (low-dose): Some POTS patients: particularly hyperadrenergic POTS with raised standing norepinephrine: benefit from low-dose propranolol (10-20 mg twice daily) to reduce the sympathetically-driven heart rate surge on standing. Not recommended as first-line for most POTS subtypes due to risk of exacerbating fatigue and exercise intolerance.

Illinois Dysautonomia Resources

At Carle Foundation Hospital in Urbana, the cardiology and neurology departments collaborate on POTS and dysautonomia evaluations. Tilt table testing is available for diagnostic confirmation. Complex cases: particularly those requiring pharmacological regimen design, genetic evaluation for hereditary connective tissue disorders (hEDS, Marfan syndrome), or assessment for autoimmune etiologies: are referred to Northwestern Medicine’s autonomic disorders program or the Rush University Medical Center dysautonomia clinic in Chicago.

This program recognizes POTS as a cardiovascular disease with complex physiology, distinct from hypertension and yet sharing the same theme: the autonomic nervous system is the common thread linking blood pressure regulation and orthostatic cardiovascular function. Understanding both hypertension and orthostatic dysregulation is essential for a complete picture of cardiovascular risk and wellbeing.

The Signal Check is fifteen questions mapping the cardiovascular risk pattern across the physiological domains most commonly missed in standard screenings. It produces a specific starting point for your next clinical conversation.